SIHUAN PHARM (00460) rose nearly 3%, with the stock up 2.29% to HK$1.34 at the time of writing. Turnover reached HK$18.04 million. The increase follows an announcement on April 20 that the group's non-wholly owned subsidiary, XUANZHUBIO-B (02575), presented data from the Phase III DIAMOND-2 study of Diraoc as a first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) in an oral presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to April 22, 2026.

The data released at the 2026 AACR meeting showed that Diraoc demonstrated statistically significant and clinically meaningful efficacy advantages in the first-line treatment of ALK-positive advanced NSCLC. In the modified intent-to-treat (mITT) population, the investigator-assessed median progression-free survival (mPFS) reached 31.3 months, significantly outperforming the control group's 12.9 months and indicating a 53% reduction in the risk of disease progression (HR=0.47, P<0.0001). Additionally, the Diraoc group achieved an objective response rate (ORR) of 88.5%, a median duration of response (mDoR) of 32.10 months, and a disease control rate (DCR) of 95.4%, with both depth and durability of tumor response significantly superior to those of the control group.